Cargando…
基因融合介导EGFR-TKI获得性耐药
Patients with sensitive epidermal growth factor receptor (EGFR) mutations often respond to tyrosine kinase inhibitors (TKIs), but acquired resistance will eventually develop. The most common mechanisms of acquired resistance include secondary EGFR mutation, MET amplification, and histologic transfor...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260378/ https://www.ncbi.nlm.nih.gov/pubmed/32429639 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.101.04 |